Bio-Rad Launches CFX Manager Software Version 1.5

Date: 
7/6/09

Enables Researchers to Easily Set Up Real-Time PCR Experiments and Analyze Data Using Bio-Rad's CFX96, CFX384, and MiniOpticon Real-Time PCR Systems

HERCULES, CA — July 6, 2009 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of its CFX Manager™ software version 1.5, a key component of Bio-Rad's 1000-series thermal cycling platform. CFX Manager software version 1.5 controls Bio-Rad's CFX96™, CFX384™, and MiniOpticon™ real-time PCR detection systems. Whether performing a first real-time PCR experiment or analyzing a comprehensive gene expression study, CFX Manager software enables researchers to easily set up experiments and analyze data.

The combination of the easy-to-use, powerful data analysis capabilities of CFX Manager software version 1.5 and the compact, portable MiniOpticon provides the ideal solution for researchers requiring medium to low throughput real-time PCR. Built on Bio Rad's MJ Mini™ thermal cycler, the MiniOpticon's two-color multiplexing capability can detect a range of fluorophores for real-time PCR applications and gel-free PCR analysis.

Pairing the CFX96 or CFX384 systems with CFX Manager software version 1.5, researchers can conduct high-throughput real-time PCR even faster. Compatible with Bio-Rad's C1000™ thermal cycler platform, the CFX96 and CFX384 systems deliver sensitive, reliable detection for real-time PCR applications, including absolute quantitation, genetic variation analysis, and gene expression.

CFX Manager software version 1.5 key features include the following:

  • Startup wizard and intuitive navigation — users are able to quickly get up and running
  • Flexible record keeping — users can enter or edit PCR plate information before, during, or after a run
  • Customizable settings — users can customize experiment setup and data analysis
  • Email notification upon run completion — users can receive an attached data file or report so they can analyze results when and where they want
  • Well Groups — users can analyze multiple experiments from a single plate, each with its own analysis settings
  • Advanced analysis tools — users can perform normalized gene expression using multiple reference genes, gene stability values, and individual reaction efficiencies

CFX Manager software version 1.5 is also available in Chinese and Russian editions. These localized language editions are the first in the real-time PCR market to display a user interface in either Chinese or Russian. The Chinese and Russian versions of the software have all of the same features as the English version of CFX Manager software version 1.5 and work with the regional language settings on both the Microsoft Windows® XP and Microsoft Windows Vista™ operating systems providing localized, language-specific environments.

For more information please visit http://www.bio-rad.com/amplification/.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

NOTE TO THE EDITOR:
Information in this release applies specifically to products available in the United States. Product availability and specifications may vary in non U.S. markets.

If you choose to review this item, your readers will receive the quickest response to their inquiries by emailing them to lsg.orders.us@bio-rad.com or by calling 1-800-424-6723.

For more information contact:
Richard Kurtz
Bio-Rad Laboratories, Inc.
800-876-3425 x5638
Richard_Kurtz@bio-rad.com

Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com